Electrolyte lawsuit dismissed
This article was originally published in The Tan Sheet
Executive Summary
The maker of elete Electrolyte Add-In is "disappointed" its complaint against Trace Minerals Research alleging unfair competition and false advertising was dismissed "due to venue issues," Mineral Resources International says Dec. 10. Ogden, Utah-based MRI alleged in a lawsuit filed in the Utah Second District Court, Weber County, that TMR improperly marketed an imitation electrolyte product called Endure as "formerly known as elete" and overstated Endure's potassium content (1"The Tan Sheet" Aug. 25, 2008, In Brief). MRI says it may appeal the court's dismissal. TMR's Web site says Endure is made "using different raw materials and processes, and has always had a different formula and mineral content than elete." The company says it corrected a manufacturing error that caused the lower potassium content
You may also be interested in...
Electrolyte competitor complaint
Mineral Resources International files a false advertising claim Aug. 20 against Trace Minerals Research, adding to a legal complaint already submitted alleging unfair competition with regard to a competing liquid electrolyte product. Ogden, Utah-based MRI says in a same-day release that TMR, a former distributor of MRI's elete Electrolyte Add-In, has been marketing an imitation electrolyte product called Endure as "formerly known as elete" and overstating Endure's potassium content. In a filing in the Utah Second District Court, Weber County, MRI has requested injunctive relief, corrective advertising and a product recall from Roy, Utah-based TMR and its eight distributors
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.